We are live on ! Find out more
CCM

Catalio Capital Management Portfolio holdings

AUM $532M
1-Year Est. Return 166.55%
This Fund
S&P 500
This Quarter Est. Return
+13.6%
1 Year Est. Return
+166.55%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$479M
AUM Growth
-$87.1M
Cap. Flow
-$83.1M
Cap. Flow %
-17.35%
Top 10 Hldgs %
54.46%
Holding
54
New
9
Increased
12
Reduced
13
Closed
13

Top Buys

Rank Stock Value
1
BBIO icon
BridgeBio Pharma
BBIO
+$31.3M
2
INCY icon
Incyte
INCY
+$18.2M
3
DFTX
Definium Therapeutics
DFTX
+$17.6M
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$15.5M
5
CRVS icon
Corvus Pharmaceuticals
CRVS
+$14.2M

Top Sells

Rank Stock Value
1
BBOT
BridgeBio Oncology
BBOT
+$31.4M
2
LLY icon
Eli Lilly
LLY
+$27.9M
3
JNJ icon
Johnson & Johnson
JNJ
+$25M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$23M
5
GILD icon
Gilead Sciences
GILD
+$17.6M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABVX
26
Abivax
ABVX
$10.4B
$5.25M 1.1%
47,193
-51,321
-52% -$6.07M
DYN icon
27
Dyne Therapeutics
DYN
$4.8B
$5.13M 1.07%
282,954
-236,761
-46% -$4.08M
ELDN icon
28
Eledon Pharmaceuticals
ELDN
$273M
$5.05M 1.06%
1,639,816
+379,996
+30% +$895K
KPTI icon
29
Karyopharm Therapeutics
KPTI
$45.8M
$5M 1.04%
897,709
+754,725
+528% +$5.75M
SUPN icon
30
Supernus Pharmaceuticals
SUPN
$2.81B
$3.21M 0.67%
62,019
-195,446
-76% -$9.95M
TARA icon
31
Protara Therapeutics
TARA
$235M
$3.02M 0.63%
580,024
-866,230
-60% -$5.13M
PHAT icon
32
Phathom Pharmaceuticals
PHAT
$775M
$2.75M 0.58%
247,767
-451,229
-65% -$5.7M
NAMS icon
33
NewAmsterdam Pharma
NAMS
$3.23B
$2.67M 0.56%
+83,554
New +$2.72M
TYRA icon
34
Tyra Biosciences
TYRA
$1.51B
$2.58M 0.54%
+67,285
New +$2.18M
IMCR icon
35
Immunocore
IMCR
$1.74B
$2.54M 0.53%
+84,352
New +$2.73M
GUTS icon
36
Fractyl Health
GUTS
$108M
$2.51M 0.53%
5,491,866
– –
HYPR icon
37
Hyperfine
HYPR
$94.7M
$1.43M 0.3%
1,320,041
– –
MGX icon
38
Metagenomi Therapeutics
MGX
$46.5M
$709K 0.15%
528,993
– –
ATAI icon
39
AtaiBeckley Inc
ATAI
$2.69B
$697K 0.15%
196,858
– –
FTH
40
Faeth Therapeutics
FTH
$836M
$464K 0.1%
14,718
– –
OM icon
41
Outset Medical
OM
$84.8M
$454K 0.09%
118,279
– –
ACLX
42
DELISTED
Arcellx
ACLX
– –
-156,109
Closed -$10.2M
ADMA icon
43
ADMA Biologics
ADMA
$2.12B
– –
-564,461
Closed -$10.3M
FULC icon
44
Fulcrum Therapeutics
FULC
$285M
– –
-201,301
Closed -$2.28M
ISRG icon
45
Intuitive Surgical
ISRG
$139B
– –
-27,209
Closed -$15.4M
JNJ icon
46
Johnson & Johnson
JNJ
$627B
– –
-120,840
Closed -$25M
LLY icon
47
Eli Lilly
LLY
$1.05T
– –
-25,923
Closed -$27.9M
OCUL icon
48
Ocular Therapeutix
OCUL
$2.2B
– –
-714,501
Closed -$8.67M
OLMA icon
49
Olema Pharmaceuticals
OLMA
$930M
– –
-267,058
Closed -$6.68M
REGN icon
50
Regeneron Pharmaceuticals
REGN
$82.7B
– –
-29,797
Closed -$23M
1
2
3

Similar funds

KI
Kapitalo Investimentos Sao Paulo, Brazil $531M AUM 25.72% 1-Year Est. Return
UFF
USA Financial Formulas Ada, Michigan $531M AUM 28.6% 1-Year Est. Return
TM
Taproot Management New York $530M AUM
SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
PDIP
Palo Duro Investment Partners Chicago, Illinois $515M AUM 36.69% 1-Year Est. Return
AGC
Aspen Grove Capital Avon, Colorado $514M AUM 21.8% 1-Year Est. Return
PP
Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return
CAM
Cander Asset Management New York $557M AUM

Catalio Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, Catalio Capital Management held 54 positions worth $479M, down 15% from $566M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Catalio Capital Management withdrew a net $83.1M in Q1 2026, closing 13 positions and reducing 13 holdings. Its most notable exit was BridgeBio Oncology, an estimated $31.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Catalio Capital Management opened a new position in BridgeBio Pharma worth $32.1M.

  • Catalio Capital Management's largest Q1 2026 buy was BridgeBio Pharma: 432,014 shares worth $32.1M.
  • Catalio Capital Management added most to Ultragenyx Pharmaceutical in Q1 2026, an estimated $15.5M increase.
  • Catalio Capital Management's biggest Q1 2026 reduction was Gilead Sciences, cutting an estimated $17.6M.
  • Catalio Capital Management fully exited BridgeBio Oncology in Q1 2026, selling an estimated $31.4M.
  • Catalio Capital Management's ten largest holdings make up 54% of its $479M portfolio in Q1 2026.
  • Catalio Capital Management opened 9 new positions and closed 13 in Q1 2026.
  • Catalio Capital Management's portfolio value fell 15% quarter-over-quarter to $479M.

Based on Catalio Capital Management's 13F filing for Q1 2026, filed 15 May 2026.